Cannabinoid Therapeutics Position AJNA BioSciences as a developer of FDA-approved botanical pharmaceuticals including cannabinoid-based treatments for autism, depression, PTSD, and other neurological conditions to engage potential partners and contract researchers seeking novel psychedelic-inspired therapeutics.

Clinical Progress Leverage ongoing phase I trials of full-spectrum psilocybin and cannabinoid compounds to identify collaboration opportunities with CROs, academic centers, and biotechs looking to co-develop or license early-stage assets with clear regulatory pathways.

Strategic Focus Target partnerships that complement a drug discovery pipeline focused on historically used plant and fungi species, offering risk mitigation in late-stage trials—a compelling angle for licensees and manufacturers seeking differentiated botanical therapies.

Funding & Scale Explore co-development and funding options with mid-market pharma players or seed-stage investors who are drawn to a lean biotech with multimodal plant-based programs and $4.4M in funding and $10–$25M in annual revenue potential.

Tech & Reach Utilize AJNA’s tech stack and digital footprint to enable targeted outreach to researchers, clinics, and suppliers in the botanical-pharma ecosystem, while prioritizing partnerships with larger players in the biotech space seeking innovation in natural-product therapeutics.